Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 13/20 | 0.44 |
| ▸ | MPO | P05164 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | FRK | P42685 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.31 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21940480 | 0.89 | S1PR2 (0.41) | S1PR2MPOKCNH2 | |
| SCHEMBL20606921 | 0.82 | S1PR2 (0.49) | S1PR2CYP1A2 | |
| SCHEMBL21940282 | 0.81 | S1PR2 (0.41) | S1PR2MPOKCNH2LRRK2LIPC | |
| Hydrochloric Acid SCHEMBL20606941 | 0.81 | S1PR2 (0.48) | S1PR2CYP1A2 | |
| SCHEMBL21940255 | 0.80 | S1PR2 (0.37) | S1PR2MPOKCNH2 | |
| SCHEMBL21941070 | 0.78 | S1PR2 (0.37) | S1PR2 | |
| SCHEMBL21941071 | 0.77 | S1PR2 (0.34) | S1PR2 | |
| SCHEMBL15473395 | 0.73 | LRRK2 (0.45) | MPOKCNH2LRRK2LIPCCYP1A2 | |
| SCHEMBL21941072 | 0.72 | S1PR2 (0.41) | S1PR2CYP1A2 | |
| SCHEMBL21940280 | 0.71 | S1PR2 (0.33) | S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423445-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2020-04-01 | — | — | EP | disclosed |